Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Japanese Journal of Clinical Oncology

Volumn 41, Issue 1, 2011, Pages 69-75

  Kondo, Masaaki ^a   Morimoto, Manabu ^a   Numata, Kazushi ^a   Nozaki, Akito ^a   Tanaka, Katsuaki ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Carcinoma; Cisplatin; Hepatocellular; Portal vein; Thrombosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA2B INTERFERON; CISPLATIN; EPIRUBICIN; FLUOROURACIL; IA CALL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONSERVATIVE TREATMENT; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG FEVER; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NAUSEA; PORTAL VEIN THROMBOSIS; POTASSIUM BLOOD LEVEL; POWDER; PROGNOSIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PALLIATIVE CARE; PORTAL VEIN; POWDERS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 78650795329     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq145     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
2. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 1993;218:145-51.
3. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
4. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783-6.
5. Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase II trial. J Hepatol 2009;51:1030-6.
6. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-8.
7. Sato M, Watanabe Y, Ueda S, Iseki S, Abe Y, Sato N, et al. Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology 1996;110:1507-14.
8. Rossi S, Di Stasi M, Buscarini L, Quaretti P, Garbagnati F, Squassante L, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am J Roentgenol 1996;167:759-68.
9. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing nonsurgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8.
10. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
11. Fujii T, Takayasu K, Muramatsu Y, Moriyama N, Wakao F, Kosuge T, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 1993;23:105-9.
12. Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 1992;16:112-7.
13. Chung JW, Park JH, Han JK, Choi BL, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. Am J Roentgenol 1995;165:315-21.
14. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002;95:588-95.
15. Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BJ, Carbone PP, et al. A randomized phase II study of mitoxantrone and cisplatin in hepatocellular cancer: an ECOG study. Cancer 1987;60:2141-5.
16. Chung YH, Song HII, Song CB, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88:1986-91.
17. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006;12:7561-7.
18. Fan J, Zhou J, Wu ZQ, Qiu SJ, Wang XY, Shi YH, et al. Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2005;11: 1215-19.
19. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989;64:1586-94.
20. Maeda S, Shibata J, Fujiyama S, Tanaka M, Noumal S, Sato K, et al. Long-term follow-up hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma. Hepatogastroenterology 2003;50:809-13.
21. Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989;97:965-71.
22. Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987;60:1194-203.
23. Ngan H, Lai CL, Fan ST, Lai EC, Yuen WK, Tso WK. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. Clin Radiol 1993;47:315-20.
24. Kajanti M, Rissanen P, Virkkunen P, Franssila K, Mantyla M. Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study. Cancer 1986;58:2386-8.
25. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 2008;38:474-83.
26. Okuda K, Musha H, Yoshida T, Kanda Y, Yamazaki T. Demonstration of growing casts of hepatocellular carcinoma in the portal vein by celiac angiography: the thread and streaks sign. Radiology 1975;117:303-9.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
28. Melia W, Wostaby D, Williams R. Diamminedichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma. Clin Oncol 1981;7:275-80.
29. Go RS, Adjei AA. Review or the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-22.
30. Court WS, Order SE, Siegel JA, Johnson E, DeNittis AS, Prinicipato R, et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002;20:613-25.
31. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002;80:143-8.
32. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009;15:3210-6.
33. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
34. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase II randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
35. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002;94:435-42.
36. Obi S, Yoshida Y, Toune R, Unuma T, Kanda M, Sato S, et al. Combination therapy of intraarterial 5-fluouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006;106:1990-7.